Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Thursday Oct 14, 2021
Thursday Oct 14, 2021
touchMDT for touchENDOCRINOLOGY
Listen to key experts from a multidisciplinary team and a patient discuss real-world use of antihyperglycemic therapies to achieve an effective combination of glycemic control, weight loss and cardiovascular benefits.
The multidisciplinary team and patient
- Diabetes nurse practitioner: Dr Shannon Idzik, USA
- Primary care specialist: Professor Stewart Harris, Canada
- Patient: Tammie Snowden, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Eli Lilly. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchendocrinologyime.org/antihyperglycemic-therapy-in-T2D-obesity-MDT-outlook//
Thursday Oct 14, 2021
Thursday Oct 14, 2021
touchMDT for touchENDOCRINOLOGY
Listen to key experts from a multidisciplinary team and a patient explore the importance of weight loss in T2D; GLP-1 RAs and SGLT2is and their association with weight loss; plus the patient’s experience of using a GLP-1 RA to manage their T2D and obesity.
The multidisciplinary team and patient
- Endocrinologist: Professor Dr med Michael Nauck, Germany
- Primary care specialist: Professor Stewart Harris, Canada
- Patient: Tammie Snowden, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Eli Lilly. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchendocrinologyime.org/antihyperglycemic-therapy-in-T2D-obesity-MDT-outlook//
Thursday Oct 14, 2021
Thursday Oct 14, 2021
touchMDT for touchENDOCRINOLOGY
Listen to key experts from a multidisciplinary team discuss the mechanism linking obesity with T2D and share their observations from the clinic on the course of disease from obesity to T2D.
The multidisciplinary team
- Primary care specialist: Professor Stewart Harris, Canada
- Endocrinologist: Professor Dr med Michael Nauck, Germany
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Eli Lilly. This activity is provided by touchIME.
For further information visit our website: https://touchendocrinologyime.org/antihyperglycemic-therapy-in-T2D-obesity-MDT-outlook//
Wednesday Oct 06, 2021
Wednesday Oct 06, 2021
touchCONGRESS for touchRESPIRATORY
Listen to Prof. Edward Garon (USA) cover key data presented at ASCO and ESMO 2021 on optimizing frontline immunotherapy for advanced NSCLC, including expert insights and interpretation from Dr Raffaele Califano (UK) and Prof. Anne-Marie Dingemans (The Netherlands).
OVERVIEW
- Data review with Prof. Garon (0:00)
- Expert interview with Dr Califano, Prof. Dingemans and Prof. Garon, answering the questions below
INTERVIEW QUESTIONS
- Based on data recently presented at ASCO21 and ESMO 2021, how do you think new and emerging immunotherapy (IO) agents will impact the frontline treatment landscape in advanced NSCLC? (35:58)
- How can key learnings from ASCO21 and ESMO 2021 be integrated into clinical practice when choosing between available IO-based regimens (e.g. IO monotherapy, IO combination therapy, and/or in addition to chemotherapy)? (43:28)
- How is our understanding of the role of PD-L1 as a biomarker in NSCLC evolving in light of recent data, and what are the possible implications for clinical practice? (48:08)
- What unmet needs remain surrounding biomarkers beyond PD-L1 in NSCLC, and what are the prospects for biomarker-driven individualized treatment decisions in future? (51:08)
- What have the latest data, including patient-reported outcomes, taught us regarding the optimal management of patients receiving frontline immunotherapy for advanced NSCLC? (57:02)
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchrespiratoryime.org/optimizing-frontline-immunotherapy-for-advanced-nsclc/
Wednesday Oct 06, 2021
Wednesday Oct 06, 2021
touchCONGRESS for touchONCOLOGY
Listen to Prof. Edward Garon (USA) cover key data presented at ASCO and ESMO 2021 on optimizing frontline immunotherapy for advanced NSCLC, including expert insights and interpretation from Dr Raffaele Califano (UK) and Prof. Anne-Marie Dingemans (The Netherlands).
OVERVIEW
- Data review with Prof. Garon (0:00)
- Expert interview with Dr Califano, Prof. Dingemans and Prof. Garon, answering the questions below
INTERVIEW QUESTIONS
- Based on data recently presented at ASCO21 and ESMO 2021, how do you think new and emerging immunotherapy (IO) agents will impact the frontline treatment landscape in advanced NSCLC? (36:02)
- How can key learnings from ASCO21 and ESMO 2021 be integrated into clinical practice when choosing between available IO-based regimens (e.g. IO monotherapy, IO combination therapy, and/or in addition to chemotherapy)? (43:32)
- How is our understanding of the role of PD-L1 as a biomarker in NSCLC evolving in light of recent data, and what are the possible implications for clinical practice? (48:11)
- What unmet needs remain surrounding biomarkers beyond PD-L1 in NSCLC, and what are the prospects for biomarker-driven individualized treatment decisions in future? (51:12)
- What have the latest data, including patient-reported outcomes, taught us regarding the optimal management of patients receiving frontline immunotherapy for advanced NSCLC? (57:06)
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/optimizing-frontline-immunotherapy-for-advanced-nsclc/
Thursday Sep 30, 2021
Thursday Sep 30, 2021
touchIN CONVERSATION for touchENDOCRINOLOGY
Listen to Dr Vincent Woo in conversation with Dr Joanna Van. They respond to questions submitted by the HCP audience and provide their expert insights on the key considerations for achieving individualized glycemic targets in patients with type 2 diabetes.
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical educational grant from Eli Lilly. The activity is provided by touchIME.
For further information visit our website: https://touchendocrinologyime.org/achieving-individualized-glycemic-targets-in-T2D
Thursday Sep 23, 2021
Thursday Sep 23, 2021
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team discuss how patients with endometrial cancer should be tested to determine suitability for PD-1/PD-L1 inhibitor therapy.
The multidisciplinary team
- Gynaecological oncologist: Prof. Nicole Concin
- Pathologist: Dr Alicia León-Castillo
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/mdt-for-io-in-ec/
Thursday Sep 23, 2021
Thursday Sep 23, 2021
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team review a patient profile and describe how they would determine suitability for PD-1/PD-L1 inhibitor therapy.
The multidisciplinary team
- Gynaecological oncologist: Prof. Nicole Concin
- Medical oncologist: Dr Antonio González-Martín
- Pathologist: Dr Alicia León-Castillo
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/mdt-for-io-in-ec/
Thursday Sep 23, 2021
Thursday Sep 23, 2021
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team discuss the latest data on PD-1/PD-L1 inhibitors and what they mean for patients with EC.
The multidisciplinary team
- Gynaecological oncologist: Prof. Nicole Concin
- Medical oncologist: Dr Antonio González-Martín
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/mdt-for-io-in-ec/
Friday Sep 17, 2021
Friday Sep 17, 2021
touchEXPERT OPINIONS for touchIMMUNOLOGY
Listen to leading experts discuss evolving treatment options for patients with advanced basal cell carcinoma, and how novel immunotherapeutic approaches within the emerging clinical study landscape may improve patient care.
The experts
- Prof. Axel Hauschild, University Hospital Schleswig-Holstein, Kiel, Germany
- Dr Emily Ruiz, Brigham and Women’s Hospital, Boston, MA, USA
- Prof. Ketty Peris, Catholic University of Rome, Rome, Italy
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical educational grant from Regeneron Pharmaceuticals, Inc. This activity is jointly provided by USF Health and touchIME.